20/20 Biolabs (NASDAQ:AIDX) Upgraded at Wall Street Zen

Posted by on Mar 17th, 2026

Wall Street Zen upgraded shares of 20/20 Biolabs (NASDAQ:AIDX – Free Report) to a hold rating in a report released on Saturday morning.

20/20 Biolabs Stock Performance

AIDX stock opened at $2.50 on Friday. 20/20 Biolabs has a 12 month low of $2.35 and a 12 month high of $50.00.

About 20/20 Biolabs

(Get Free Report)

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.

Featured Stories

Receive News & Ratings for 20/20 Biolabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 20/20 Biolabs and related companies with MarketBeat.com's FREE daily email newsletter.